Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Cdmogen Co. Ltd. manages a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 2 pending office actions, which are being reviewed by 2 distinct examiners. This distribution indicates that each pending matter is being handled by a different individual, providing a degree of variety in the examination process. These actions are also split between 2 distinct art units, suggesting that the company's biotechnological innovations fall into two different specialized categories at the patent office.
The busiest examiner for this portfolio is SAPKOTA, SURAJ, who is currently handling 1 busiest examiner pending action. Given that there are 2 pending office actions in total, the workload is split between the 2 distinct examiners. For a practitioner, this means that the company is not overly reliant on a single examiner's interpretation for its entire pending workload. The involvement of 2 distinct art units further ensures that the 2 pending office actions are being evaluated under different technical standards. Each of the distinct examiners is responsible for one of the pending office actions, creating a balanced prosecution environment.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SAPKOTA, SURAJ | 1 | 0.0% | +0.0% |
| VIVLEMORE, TRACY ANN | 1 | 73.0% | +6.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18365015 | COMPOSITION COMPRISING RAAV CONTAINING SOLUBLE VEGFR-1 VARIANT CDNA FOR TREATMENT OF MACULAR DEGENERATION | VIVLEMORE, TRACY ANN | 9d overdue |
| 18536423 | COMPOSITION FOR TREATING DIABETIC RETINOPATHY CONTAINING scAAV2-shmTOR-SD (CRG-01) | SAPKOTA, SURAJ | — |
| Art Unit | Apps |
|---|---|
| 4100 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18536423 | COMPOSITION FOR TREATING DIABETIC RETINOPATHY CONTAINING scAAV2-shmTOR-SD (CRG-01) | SAPKOTA, SURAJ | 4100 | §103§112 | Non-Final OA | — | Pending | Dec 12, 2023 |
| 18365015 | COMPOSITION COMPRISING RAAV CONTAINING SOLUBLE VEGFR-1 VARIANT CDNA FOR TREATMENT OF MACULAR DEGENERATION | VIVLEMORE, TRACY ANN | 1638 | §103§112 | Non-Final OA | 9d overdue | Pending | Aug 03, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial